US5585362A
(en)
*
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
CA2145641C
(en)
*
|
1992-12-03 |
2008-05-27 |
Richard J. Gregory |
Pseudo-adenovirus vectors
|
WO1994023582A1
(en)
*
|
1993-04-08 |
1994-10-27 |
Genetic Therapy, Inc. |
Adenoviral vectors including dna encoding lung surfactant protein
|
US6133028A
(en)
*
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
ATE322547T1
(de)
|
1993-06-10 |
2006-04-15 |
Genetic Therapy Inc |
Adenovirale vektoren für die behandlung der hämophilie
|
US20020136708A1
(en)
|
1993-06-24 |
2002-09-26 |
Graham Frank L. |
System for production of helper dependent adenovirus vectors based on use of endonucleases
|
ES2310924T3
(es)
*
|
1993-07-13 |
2009-01-16 |
Centelion |
Vectores adenovirales defectivos y utilizacion en terapia genica.
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
US5698443A
(en)
*
|
1995-06-27 |
1997-12-16 |
Calydon, Inc. |
Tissue specific viral vectors
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
DE69533295T3
(de)
*
|
1994-02-16 |
2009-07-16 |
The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services |
Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
WO1995029993A1
(en)
*
|
1994-04-28 |
1995-11-09 |
The University Of Michigan |
Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
|
US6451571B1
(en)
|
1994-05-02 |
2002-09-17 |
University Of Washington |
Thymidine kinase mutants
|
US5851806A
(en)
*
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
DE69535178T2
(de)
*
|
1994-06-10 |
2006-12-14 |
Genvec, Inc. |
Adenoviren-vektor systeme und zelllinien
|
EP1369487A3
(en)
*
|
1994-08-16 |
2004-04-07 |
Crucell Holland B.V. |
Recombinant vectors derived from adenovirus for use in gene therapy
|
FR2725213B1
(fr)
*
|
1994-10-04 |
1996-11-08 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation en therapie genique
|
FR2725726B1
(fr)
|
1994-10-17 |
1997-01-03 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en therapie genique
|
FR2726285B1
(fr)
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
|
DE69534166T2
(de)
*
|
1994-10-28 |
2006-03-09 |
Trustees Of The University Of Pennsylvania |
Rekombinanter adenovirus und methoden zu dessen verwendung
|
US5872005A
(en)
*
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
AU709498B2
(en)
*
|
1994-12-12 |
1999-09-02 |
Genetic Therapy, Inc. |
Improved adenoviral vectors and producer cells
|
FR2729674B1
(fr)
*
|
1995-01-20 |
1997-04-11 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
FR2738575B1
(fr)
*
|
1995-09-08 |
1997-10-10 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
FR2741891B1
(fr)
*
|
1995-06-01 |
1998-01-09 |
Centre Nat Rech Scient |
Cellules pour la production d'adenovirus recombinants
|
IL116816A
(en)
*
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
FR2730411B1
(fr)
*
|
1995-02-14 |
1997-03-28 |
Centre Nat Rech Scient |
Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
FR2731710B1
(fr)
*
|
1995-03-14 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
|
JP3770333B2
(ja)
*
|
1995-03-15 |
2006-04-26 |
大日本住友製薬株式会社 |
組換えdnaウイルスおよびその製造方法
|
US5707618A
(en)
*
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
WO1996033280A1
(en)
*
|
1995-04-17 |
1996-10-24 |
Board Of Regents, The University Of Texas System |
An adenovirus helper-virus system
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
AU6261696A
(en)
*
|
1995-06-05 |
1996-12-24 |
Trustees Of The University Of Pennsylvania, The |
A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5698202A
(en)
*
|
1995-06-05 |
1997-12-16 |
The Wistar Institute Of Anatomy & Biology |
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
|
US5985846A
(en)
*
|
1995-06-07 |
1999-11-16 |
Baylor College Of Medicine |
Gene therapy for muscular dystrophy
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
DK1445322T4
(da)
*
|
1995-06-15 |
2012-09-03 |
Crucell Holland Bv |
Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi
|
FR2735789B1
(fr)
*
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
HUP9901908A3
(en)
|
1995-07-17 |
2000-02-28 |
Univ Texas |
P16 expression constructs and their application in cancer therapy
|
US7163925B1
(en)
|
1995-07-17 |
2007-01-16 |
Board Of Regents, The University Of Texas System |
p16 expression constructs and their application in cancer therapy
|
FR2737222B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
FR2737221B1
(fr)
*
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux pour la therapie genique
|
US6261554B1
(en)
|
1995-07-25 |
2001-07-17 |
Introgene B.V. |
Compositions for targeted gene delivery
|
US5837511A
(en)
*
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
US6004797A
(en)
*
|
1995-11-09 |
1999-12-21 |
Avigen, Inc. |
Adenovirus helper-free recombinant AAV Virion production
|
JP2006075171A
(ja)
*
|
1995-11-09 |
2006-03-23 |
Avigen Inc |
組換えaavビリオン産生における使用のための補助機能
|
US5891690A
(en)
*
|
1996-04-26 |
1999-04-06 |
Massie; Bernard |
Adenovirus E1-complementing cell lines
|
WO1997045550A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Baxter International Inc. |
Mini-adenoviral vector
|
JP2000514290A
(ja)
*
|
1996-07-01 |
2000-10-31 |
ローヌ―プーラン・ロレ・エス・アー |
組換えアデノウイルスの製造方法
|
FR2750433B1
(fr)
*
|
1996-07-01 |
1998-08-14 |
Rhone Poulenc Rorer Sa |
Procede de production d'adenovirus recombinants
|
US20040156861A1
(en)
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US7008776B1
(en)
*
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
IL129986A0
(en)
|
1996-12-06 |
2000-02-29 |
Rhone Poulenc Rorer Pharma |
Polypeptides encoded by a human lipase-like gene compositions and methods
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
WO1998037185A2
(en)
*
|
1997-02-20 |
1998-08-27 |
The Board Of Regents Of The University Of Texas System |
Vectors for controlled gene expression
|
FR2761689B1
(fr)
|
1997-04-02 |
1999-06-25 |
Transgene Sa |
Fibre adenovirale modifiee et adenovirus cibles
|
KR20010020342A
(ko)
|
1997-04-28 |
2001-03-15 |
자끄 사비나 |
종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
WO1998054345A1
(en)
*
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
CA2307016A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Life Technologies, Inc. |
Recombinational cloning using nucleic acids having recombination sites
|
US6653088B1
(en)
|
1997-10-24 |
2003-11-25 |
Aventis Pharma S.A. |
Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
|
EP2278006A3
(en)
|
1997-11-06 |
2011-03-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Neisserial antigens
|
PT1049767E
(pt)
|
1998-01-08 |
2005-10-31 |
Agronomique Inst Nat Rech |
Coelho transgenico que expressa uma lipoproteina (a) humana funcional
|
JP4399112B2
(ja)
|
1998-01-14 |
2010-01-13 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
NeisseriaMeningitidis抗原
|
ATE344322T1
(de)
|
1998-02-13 |
2006-11-15 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP2261351A3
(en)
|
1998-05-01 |
2012-01-11 |
Novartis Vaccines and Diagnostics, Inc. |
Neisseria meningitidis antigens and compositions
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US6328958B1
(en)
|
1998-08-28 |
2001-12-11 |
Duke University |
Deleted adenovirus vectors and methods of making and administering the same
|
DE19856065A1
(de)
*
|
1998-12-04 |
2000-06-15 |
Centeon Pharma Gmbh |
Rekombinanter, adenoviraler Vektor mit limitierter Autoreplikationsfähigkeit in vivo
|
US6225113B1
(en)
*
|
1998-12-04 |
2001-05-01 |
Genvec, Inc. |
Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
|
FR2787465A1
(fr)
*
|
1998-12-21 |
2000-06-23 |
Transgene Sa |
Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
EP1016726A1
(en)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gene therapy to promote angiogenesis
|
EP1157103A2
(en)
*
|
1999-02-18 |
2001-11-28 |
Merck & Co., Inc. |
Production of helper dependent adenovirus vectors based on use of endonucleases
|
ES2162551B1
(es)
*
|
1999-04-09 |
2002-07-01 |
Univ Madrid Autonoma |
Procedimiento para la replicacion selectiva de adenovirus defectivos en celulas tumorales.
|
US6490775B1
(en)
*
|
1999-04-23 |
2002-12-10 |
Veri-Tek Inc. |
Press operation verification system
|
EP2290083B1
(en)
|
1999-04-30 |
2014-08-20 |
Novartis Vaccines and Diagnostics S.r.l. |
Conserved neisserial antigens
|
US7226786B2
(en)
|
1999-05-18 |
2007-06-05 |
Dnavec Research Inc. |
Envelope gene-deficient Paramyxovirus vector
|
US20030166252A1
(en)
*
|
1999-05-18 |
2003-09-04 |
Kaio Kitazato |
Paramyxovirus-derived RNP
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
FR2794771B1
(fr)
*
|
1999-06-11 |
2001-08-10 |
Aventis Pharma Sa |
Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
|
WO2001002607A1
(en)
*
|
1999-07-06 |
2001-01-11 |
Merck & Co., Inc. |
Adenovirus carrying gag gene hiv vaccine
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
FR2799472B1
(fr)
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
BR0015137A
(pt)
|
1999-10-29 |
2003-03-25 |
Chiron Spa |
Peptìdeos antigênicos de neisseria
|
CN1254719A
(zh)
*
|
1999-11-19 |
2000-05-31 |
钱其军 |
一种缺陷型腺病毒及其构建方法
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
DK2289545T3
(da)
|
2000-01-17 |
2016-09-05 |
Glaxosmithkline Biologicals Sa |
Suppleret OMV-vaccine mod meningococcus
|
IL151987A0
(en)
|
2000-03-31 |
2003-04-10 |
Aventis Pharma Inc |
Nuclear factor kb inducing factor
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
EP1167533A1
(en)
*
|
2000-06-23 |
2002-01-02 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Methods and means for the complementation of viral protein expression in stable cell lines
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6733993B2
(en)
*
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
AU2001294562B2
(en)
*
|
2000-09-15 |
2007-05-24 |
Merck & Co., Inc. |
Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
AU2002214127B2
(en)
|
2000-10-27 |
2007-06-07 |
J. Craig Venter Institute, Inc. |
Nucleic acids and proteins from streptococcus groups A and B
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
JP2002142770A
(ja)
*
|
2000-11-08 |
2002-05-21 |
Dnavec Research Inc |
循環系への遺伝子送達用パラミクソウイルスベクター
|
IL155726A0
(en)
|
2000-12-28 |
2003-11-23 |
Wyeth Corp |
Recombinant protective protein from streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AUPR518501A0
(en)
|
2001-05-22 |
2001-06-14 |
Unisearch Limited |
Yin yang-1
|
US6677156B2
(en)
|
2001-07-23 |
2004-01-13 |
Genvec, Inc. |
Non-adenoviral gene product-based complementing cells for adenoviral vectors
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
CA2469620A1
(en)
|
2001-12-12 |
2003-06-19 |
Chiron Srl. |
Immunisation against chlamydia trachomatis
|
US20030158112A1
(en)
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
DE60323080D1
(de)
*
|
2002-04-25 |
2008-10-02 |
Crucell Holland Bv |
Stabile adenovirale vektoren und methoden für deren vermehrung
|
CA2484287A1
(en)
*
|
2002-04-30 |
2003-11-13 |
Dnavec Research Inc. |
Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
JP2005532829A
(ja)
*
|
2002-07-18 |
2005-11-04 |
インヴィトロジェン コーポレーション |
組換え部位を含むウイルスベクター
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
EP1561819A4
(en)
*
|
2002-10-24 |
2006-03-22 |
Dnavec Research Inc |
METHOD FOR TRANSMITTING A GENE IN T CELLS
|
CN1756845A
(zh)
|
2002-11-12 |
2006-04-05 |
A·B·德塞罗斯 |
腺病毒载体疫苗
|
EP1594459B1
(en)
|
2002-12-30 |
2010-02-17 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
DE602004025810D1
(de)
*
|
2003-06-30 |
2010-04-15 |
Dnavec Research Inc |
Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
|
BRPI0412279A
(pt)
*
|
2003-07-02 |
2006-09-19 |
Diversa Corp |
glucanases, ácidos nucléicos codificando as mesmas e métodos para preparar e aplicar os mesmos
|
US7026164B2
(en)
*
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
US7790445B2
(en)
|
2003-07-21 |
2010-09-07 |
Transgene S.A. |
Polypeptide having an improved cytosine deaminase activity
|
ATE497974T1
(de)
|
2003-07-21 |
2011-02-15 |
Transgene Sa |
Multifunktionelle cytokine
|
CA2544946A1
(en)
|
2003-11-24 |
2005-03-06 |
Sidney Kimmel Cancer Center |
Mucin antigen vaccine
|
ATE469984T1
(de)
*
|
2003-12-01 |
2010-06-15 |
Life Technologies Corp |
Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
US20050163755A1
(en)
*
|
2003-12-15 |
2005-07-28 |
Moy Alan B. |
Methods and compositions related to 1-caldesmon
|
KR20070004637A
(ko)
*
|
2004-01-22 |
2007-01-09 |
가부시키가이샤 디나벡크 겐큐쇼 |
바이러스 벡터의 제조방법
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
EP1780269B1
(en)
*
|
2004-02-23 |
2009-07-08 |
Crucell Holland B.V. |
Virus purification methods
|
EP1736541B1
(en)
|
2004-03-29 |
2013-01-23 |
Galpharma Co., Ltd. |
Novel modified galectin 9 protein and use thereof
|
EP2567967A3
(en)
|
2004-04-12 |
2013-08-21 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Method of using adenoviral vectors to induce an immune response
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
WO2006020071A2
(en)
|
2004-07-16 |
2006-02-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Vaccines against aids comprising cmv/r-nucleic acid constructs
|
CN101027662A
(zh)
*
|
2004-08-04 |
2007-08-29 |
阿菲克姆智能牧场管理系统公司 |
用于在限定区域内定位物体的方法和系统
|
CA2597647A1
(en)
|
2005-02-11 |
2007-08-02 |
University Of Southern California |
Method of expressing proteins with disulfide bridges
|
AU2006233800B2
(en)
*
|
2005-04-11 |
2011-07-07 |
Crucell Holland B.V. |
Virus purification using ultrafiltration
|
ES2564823T3
(es)
|
2005-05-27 |
2016-03-29 |
Ospedale San Raffaele S.R.L. |
Vector génico que comprende miARN
|
WO2006130525A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
US8765146B2
(en)
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
WO2007030588A1
(en)
*
|
2005-09-07 |
2007-03-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of replicators to prevent gene silencing
|
SI1950307T1
(sl)
|
2005-10-28 |
2016-02-29 |
Id Pharma Co., Ltd. |
Transfer gena v epitelijsko matično celico dihalnih poti z uporabo lentivirusnega vektorja, psevdotipiziranega z RNA virusnim spike proteinom
|
WO2007056266A2
(en)
*
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
Cd40 ligand fusion protein vaccine
|
EP1951297A2
(en)
|
2005-11-10 |
2008-08-06 |
GenVec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
WO2007130501A2
(en)
*
|
2006-05-01 |
2007-11-15 |
University Of Southern California |
Combination therapy for treatment of cancer
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
AU2007276793B2
(en)
|
2006-07-28 |
2014-01-16 |
Sanofi |
Composition and method for treatment of tumors
|
CA2666682C
(en)
|
2006-10-19 |
2014-07-08 |
Merck & Co., Inc. |
Anti-il-13r.alpha.1 antibodies and their uses thereof
|
CA2666679C
(en)
|
2006-10-19 |
2016-06-07 |
Merck & Co., Inc. |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
CN101617052A
(zh)
|
2007-01-30 |
2009-12-30 |
特兰斯吉恩股份有限公司 |
用于免疫的乳头瘤病毒e2多肽
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
ES2337973B8
(es)
|
2008-05-16 |
2011-07-21 |
Proyecto De Biomedicina Cima, S.L. |
Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
|
BRPI0921651A2
(pt)
*
|
2008-11-03 |
2015-08-18 |
Crucell Holland Bv |
Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
WO2010056901A2
(en)
|
2008-11-13 |
2010-05-20 |
University Of Southern California |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
EP2387414A1
(en)
|
2009-01-13 |
2011-11-23 |
Transgene SA |
Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
|
HUE025015T2
(en)
|
2009-01-20 |
2016-04-28 |
Transgene Sa |
Soluble in ICAM-1 as a biomarker for predicting therapeutic response
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
KR20110138354A
(ko)
|
2009-03-24 |
2011-12-27 |
트랜스진 에스.에이. |
환자를 모니터링하기 위한 바이오마커
|
PL2419728T3
(pl)
|
2009-04-17 |
2014-05-30 |
Transgene Sa |
Biomarker do monitorowania pacjentów
|
US9261512B2
(en)
|
2009-07-10 |
2016-02-16 |
Transgene, S.A. |
Biomarker for treating cancer patients
|
MX2012001592A
(es)
|
2009-08-07 |
2012-05-22 |
Transgene Sa |
Composicion para el tratamiento de la infección del virus de la hepatitis b.
|
CA2777116C
(en)
|
2009-10-15 |
2020-09-01 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
KR101749779B1
(ko)
|
2009-10-15 |
2017-06-21 |
크루셀 홀란드 비.브이. |
아데노바이러스 입자의 정제 방법
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
EP2853266B1
(en)
|
2009-11-09 |
2018-01-31 |
Genvec, Inc. |
Method of propagating monkey adenoviral vectors
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
CN102762721B
(zh)
|
2010-02-15 |
2015-03-11 |
克鲁塞尔荷兰公司 |
用于生产Ad26腺病毒载体的方法
|
ES2887335T3
(es)
|
2010-03-17 |
2021-12-22 |
Univ Cornell |
Vacuna contra las drogas de abuso basada en adenovirus alterado
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
EP2608805B1
(en)
|
2010-08-23 |
2017-07-05 |
Wyeth LLC |
STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
|
ES2585328T5
(es)
|
2010-09-10 |
2022-12-14 |
Wyeth Llc |
Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
|
EP2618838A1
(en)
|
2010-09-20 |
2013-07-31 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
US8911975B2
(en)
|
2011-02-08 |
2014-12-16 |
Mie University |
Method for producing virus vector for gene transfer
|
JPWO2012147370A1
(ja)
*
|
2011-04-28 |
2014-07-28 |
国立大学法人山口大学 |
ターミネータ配列を含む高発現用リバースプライマー及びリニアdna
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Hbv聚合酶突變體
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
TW201321016A
(zh)
|
2011-09-29 |
2013-06-01 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
|
CA2850629C
(en)
|
2011-10-05 |
2024-05-21 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
CN103987726B
(zh)
|
2011-10-05 |
2017-10-03 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
WO2013052811A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vectors and methods of use
|
EP2764011B1
(en)
|
2011-10-05 |
2021-04-07 |
GenVec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2809346A1
(en)
|
2012-02-02 |
2014-12-10 |
GenVec, Inc. |
Adenoviral vector-based malaria vaccine
|
JP5925342B2
(ja)
|
2012-03-09 |
2016-05-25 |
ファイザー・インク |
髄膜炎菌(Neisseriameningitidis)組成物およびその方法
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
SG11201405228VA
(en)
|
2012-03-12 |
2014-11-27 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
SG11201405803PA
(en)
|
2012-03-22 |
2014-11-27 |
Crucell Holland Bv |
Vaccine against rsv
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
WO2013181128A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Modified serotype 28 adenoviral vectors
|
MY173004A
(en)
|
2012-07-10 |
2019-12-18 |
Transgene Sa |
Mycobacterial antigen vaccine
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
EP3587455A1
(en)
|
2012-10-23 |
2020-01-01 |
Emory University |
Gm-csf and il-4 conjugates, compositions, and methods related thereto
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
WO2014164703A1
(en)
|
2013-03-11 |
2014-10-09 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for occular inflammation
|
RS58436B1
(sr)
|
2013-04-25 |
2019-04-30 |
Janssen Vaccines & Prevention Bv |
Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
|
KR102313153B1
(ko)
|
2013-06-17 |
2021-10-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 예비융합 rsv f 폴리펩타이드
|
KR102199096B1
(ko)
|
2013-09-08 |
2021-01-06 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
EA036046B1
(ru)
|
2013-09-19 |
2020-09-18 |
Янссен Вэксинс Энд Превеншн Б.В. |
Композиция для стабилизации количества, эффективности, инфекционности и качества аденовирусов
|
CN106103471B
(zh)
|
2014-01-09 |
2020-01-07 |
特兰斯吉恩股份有限公司 |
异源寡聚分枝杆菌抗原的融合
|
WO2015127094A1
(en)
|
2014-02-19 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
PT3215187T
(pt)
|
2014-11-04 |
2018-11-27 |
Janssen Vaccines & Prevention Bv |
Vacinas terapêuticas contra hpv16
|
EP3236998A1
(en)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Recombinant metapneumovirus f proteins and their use
|
CN107406835A
(zh)
|
2015-01-20 |
2017-11-28 |
美利坚合众国,由健康及人类服务部部长代表 |
表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
|
WO2016132294A1
(en)
|
2015-02-19 |
2016-08-25 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
LT3271729T
(lt)
|
2015-03-18 |
2021-02-25 |
Janssen Vaccines & Prevention B.V. |
Rekombinantinių raiškos sistemų analizės būdai
|
CA2982105A1
(en)
|
2015-04-07 |
2016-10-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods for inducing cell division of postmitotic cells
|
PL3283634T3
(pl)
|
2015-04-14 |
2019-10-31 |
Janssen Vaccines & Prevention Bv |
Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsv fポリペプチド
|
PL3319633T3
(pl)
|
2015-07-07 |
2021-04-19 |
Janssen Vaccines & Prevention B.V. |
Szczepionka przeciwko rsv
|
MY195389A
(en)
|
2015-08-20 |
2023-01-18 |
Janssen Vaccines & Prevention Bv |
Therapeutic HPV18 Vaccines
|
EP3359132B1
(en)
|
2015-10-06 |
2023-08-16 |
Janssen Vaccines & Prevention B.V. |
Methods for preventing plastic-induced degradation of biologicals
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
US10808011B2
(en)
|
2016-03-09 |
2020-10-20 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant HIV-1 envelope proteins and their use
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
LT3439672T
(lt)
|
2016-04-05 |
2021-01-25 |
Janssen Vaccines & Prevention B.V. |
Stabilizuotas tirpus rsv f baltymas prieš suliejimą, skirtas naudoti rsv infekcijos profilaktikai
|
WO2017192418A1
(en)
|
2016-05-02 |
2017-11-09 |
Janssen Vaccine & Prevention B.V. |
Therapeutic hpv vaccine combinations
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
EP3455358B1
(en)
|
2016-05-12 |
2020-08-26 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
MY194419A
(en)
|
2016-05-30 |
2022-11-30 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins
|
BR112018075969A2
(pt)
|
2016-06-20 |
2019-04-02 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
WO2018064523A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
EP3518968B1
(en)
|
2016-10-03 |
2022-01-05 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Hiv-1 env fusion peptide immunogens and their use
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
US10960070B2
(en)
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
CN110418650A
(zh)
|
2016-11-16 |
2019-11-05 |
免疫治疗有限公司 |
用于治疗过敏的核酸
|
CA3043790A1
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
PE20191107A1
(es)
|
2017-01-31 |
2019-08-26 |
Pfizer |
Composiciones de neisseria meningitidis y metodos respectivos
|
EP3580340A1
(en)
|
2017-02-09 |
2019-12-18 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
EP3600405A1
(en)
|
2017-03-24 |
2020-02-05 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of hiv-1 gp120 and their use
|
CN110799529A
(zh)
|
2017-04-22 |
2020-02-14 |
免疫治疗有限公司 |
改良lamp构建物
|
US20200087365A1
(en)
|
2017-05-02 |
2020-03-19 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising cancer antigens
|
US11229692B2
(en)
|
2017-05-17 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
KR20200053518A
(ko)
|
2017-09-15 |
2020-05-18 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 면역의 안전한 유도를 위한 방법
|
EP3697905A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
WO2019079337A1
(en)
|
2017-10-16 |
2019-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
|
MX2020004488A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
JP7285833B2
(ja)
|
2017-10-31 |
2023-06-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルス及びその用途
|
KR20200083510A
(ko)
|
2017-10-31 |
2020-07-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 및 이의 용도
|
US11459583B2
(en)
|
2017-10-31 |
2022-10-04 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
SI3743106T1
(sl)
|
2018-01-23 |
2022-10-28 |
Janssen Vaccines & Prevention B. V. |
Cepiva proti virusu influence in njihove uporabe
|
CA3092935A1
(en)
|
2018-03-06 |
2019-09-12 |
Precigen, Inc. |
Hepatitis b vaccines and uses of the same
|
JP2021523185A
(ja)
|
2018-05-15 |
2021-09-02 |
イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. |
アレルゲンを含む改善されたlamp構築物
|
US20210361318A1
(en)
|
2018-07-02 |
2021-11-25 |
Voyager Therapeutics, Inc. |
Cannula system and use thereof
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
US20210340188A1
(en)
|
2018-10-22 |
2021-11-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Recombinant gp120 protein with v1-loop deletion
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020263900A1
(en)
|
2019-04-25 |
2021-10-14 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
KR20220008816A
(ko)
|
2019-05-15 |
2022-01-21 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
EP4025247A1
(en)
|
2019-09-05 |
2022-07-13 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
KR20220076497A
(ko)
|
2019-10-03 |
2022-06-08 |
얀센 백신스 앤드 프리벤션 비.브이. |
아데노바이러스 벡터 및 이의 용도
|
EP4041873A4
(en)
|
2019-10-08 |
2023-10-25 |
Trustees of Boston College |
PROTEINS CONTAINING MULTIPLE DIFFERENT NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING SUCH PROTEINS
|
JP2022551732A
(ja)
|
2019-10-18 |
2022-12-13 |
イミュノミック セラピューティックス, インコーポレイテッド |
がん抗原を含む改良lamp構築物
|
BR112022009598A2
(pt)
|
2019-11-18 |
2022-08-16 |
Janssen Biotech Inc |
Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
|
CA3170322A1
(en)
|
2020-02-11 |
2021-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 vaccine
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
EP4135757A1
(en)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
CN116096407A
(zh)
|
2020-04-29 |
2023-05-09 |
美国政府(由卫生和人类服务部的部长所代表) |
重组人偏肺病毒f蛋白及其用途
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
EP4175721A1
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
CN116322740A
(zh)
|
2020-07-13 |
2023-06-23 |
特兰斯吉恩股份有限公司 |
免疫抑制的治疗
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
WO2022232648A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
JP2024516400A
(ja)
|
2021-04-30 |
2024-04-15 |
カリヴィル イムノセラピューティクス, インコーポレイテッド |
修飾されたmhc発現のための腫瘍溶解性ウイルス
|
EP4380613A1
(en)
|
2021-08-03 |
2024-06-12 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
US20230277600A1
(en)
|
2021-10-20 |
2023-09-07 |
University Of Rochester |
Treatment Of Age-Related White Matter Loss By Competitive Replacement Of Glial Cells
|
CA3236365A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|